26. Kabe Y., Nakane T., Koike I. et al. Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance // Nature Communications. 2016. № 7. P. 11030.
27. Terzaghi L., Tessaro I., Raucci F. et al. PGRMC1 participates in late events of bovine granulosa cells mitosis and oocyte meiosis // Cell Cycle. 2016. Vol. 15, № 15. P. 2019–2032. doi: 10.1080/15384101.2016.1192731.
28. Bali N., Morgan T.E., Finch C.E. Pgrmc1: New roles in the microglial mediation of progesterone-antagonism of estradiol-dependent neurite sprouting and in microglial activation // Front Neurosci. 2013. № 7. P. 157.
29. Runko E., Kaprielian Z. Caenorhabditis elegans VEM-1, a novel membrane protein, regulates the guidance of ventral nerve cord-associated axons // J Neurosci. 2004. Vol. 24. P. 9015–9026.
30. Elassar A., Liu X., Scranton V. et al. The relationship between follicle development and progesterone receptor membrane component-1 expression in women undergoing in vitro fertilization // Fertil Steril. 2012. № 97. P. 572–578.
31. Oda S., Nakajima M., Toyoda Y. et al. Progesterone receptor membrane component 1 modulates human cytochrome p450 activities in an isoform-dependent manner // Drug Metab Dispos. 2011. Vol. 39. P. 2057–2065.
32. Jackson A.C., Wyse S.L., Roche et al. Progesterone receptor signalling in retinal photoreceptor neuroprotection // J Neurochem. 2016. № 136. P. 63–77.
33. Kimura I., Nakayama Y., Konishi M. et al. Functions of MAPR (membrane-associated progesterone receptor) family members as heme/steroid-binding proteins // Curr Protein Pept Sci, 2012. № 13. P. 687–696.
34. Clark N.C., Friel A.M., Pru C.A. et al. Progesterone receptor membrane component 1 promotes survival of human breast cancer cells and the growth of xenograft tumors // Cancer Biol Ther. 2016. № 17. P. 262–271.
35. Neubauer H., Ruan X., Schneck H. et al. Overexpression of progesterone receptor membrane component 1: Possible mechanism for increased breast cancer risk with norethisterone in hormone therapy // Menopause, 2013. Vol. 20. P. 504–510.
36. Zhao G., Yan G., Cheng J. et al. Hyaluronic acid prevents immunosuppressive drug-induced ovarian damage via up-regulating PGRMC1 expression // Sci Rep. 2015. Vol. 5. P. 7647.
37. Wang J.L., Li S.L., Qin Y.Y., Chen Z.J., Analysis of progesterone receptor membrane component 1 mutation in Han Chinese women with premature ovarian failure // Reprod Biomed Online. 2014. Vol. 29. P. 640–643.
38. Peluso J.J., Yuan A., Liu X., Lodde V. Plasminogen activator inhibitor 1 RNA-binding protein interacts with progesterone receptor membrane component 1 to regulate progesterone’s ability to maintain the viability of spontaneously immortalized granulosa cells and rat granulosa cells // Biol Reprod. 2013. Vol. 88, № 1. P. 20. doi: 10.1095/biolreprod.112.103036.
39. Shih C.C., Chou H.C., Chen Y.J. et al. Role of PGRMC1 in cell physiology of cervical cancer // Life Sci. 2019. Vol. 231. P. 116541. doi: 10.1016/j.lfs.2019.06.016.
40. Stöckli J., Fazakerley D.J., James D.E. GLUT4 exocytosis // J Cell Sci. 2011. Vol. 124. P. 4147–4159.
41. Ahmed I.S., Chamberlain C., Craven R.J. S2R (Pgrmc1): The cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling // Expert Opin Drug Metab Toxicol. 2012. № 8. P. 361–370.
42. Thomas P., Pang Y., Dong J. et al. Steroid and G protein binding characteristics of the seatrout and human progestin membrane receptor alpha subtypes and their evolutionary origins // Endocrinology. 2007. Vol. 148. № 2. P. 705–718. doi: 10.1210/en.2006-0974.
43. Makvandi M., Tilahun E.D., Lieberman B.P., et al. The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer // Biochem Biophys Res Commun, 2015. № 467. P. 1070–1075.
44. Ruan X., Neubauer H., Yang Y. et al. Progestogens and membrane-initiated effects on the proliferation of human breast cancer cells // Climacteric. 2012. Vol. 15. P. 467–472.
45. Mittelman-Smith M.A., Rudolph L.M., Mohr M.A., Micevych P.E. Rodent Models of Non-classical Progesterone Action Regulating Ovulation // Front Endocrinol (Lausanne). 2017. Jul 24; 8: 165. doi: 10.3389/fendo.2017.00165.
46. Hampton K.K., Craven R.J. Pathways driving the endocytosis of mutant and wild-type EGFR in cancer // Oncoscience. 2014. № 1. P. 504–512.
47. Min L., Strushkevich N.V., Harnastai I.N. et al. Molecular identification of adrenal inner zone antigen as a heme-binding protein // FEBS J. 2005. Vol. 272. P. 5832–5843.
48. Yoshitani N., Satou K., Saito S. et al. A structure-based strategy for discovery of small ligands binding to functionally unknown proteins: combination of in silico screening and surface plasmon resonance measurements // Proteomics, 2005. Vol. 5. P. 1472–1480.
49. Elbein S.C., Kern P.A., Rasouli N. et al. Global gene expression profiles of subcutaneous adipose and muscle from glucose-tolerant, insulin-sensitive, and insulin-resistant individuals matched for BMI // Diabetes. 2011. № 60. P. 1019–1029.